Discuss cutting-edge small molecule strategies capable of interacting with and modulating RNA with improved specificity, selectivity and drug-like properties.
It's our earlybird savings week for both the 2nd TPD Europe Summit & 4th RNA Targeted Drug Discovery Summit. Register this week to save on your place! Bring your team & get additional group savings of up to 20%!
RNA: https://t.co/U1mHpSScpw
TPD Europe: https://t.co/tnBHiP6Tkp
Did you know at the 4th RNA Targeted Drug Discovery Summit we have 3 comprehensive, deep-dive collaborative workshop sessions as well as our 2-day conference? Find out more here: https://t.co/dNLIrg31zT
Check out the 2021 agenda for the RNA Targeted Drug Discovery Summit taking place virtually this December!
3 days of content, 160+ attendees and counting, expert speakers from @AnimaBiotech, @rnarevealed, @expansionrx & many more!
https://t.co/8e6gGjkMuA
Wesley Blackaby, VP Chemistry will be participating @RNA_TDD Summit! He'll be discussing 'Drugging #RNA modifying #enzymes' today at 11:30am EST https://t.co/mA5fvKHpa7
Have you seen this year's event guide for the 3rd RNA- Targeted Drug Discovery Summit yet? Find out who this year’s expert speakers are and everything that they will be discussing - access your free copy here: https://t.co/DgKxQ8H7rJ
We caught up with our speakers from @ArrakisTx, Saverna Therapeutics & @abbvie to find out more about their #RNA work, the challenges the field is facing and where the biggest opportunities lie as the field progresses! Access the full interviews here: https://t.co/1S1AzNLoJQ
COVID messenger-RNA vaccine: Early findings in older adults. Moderna vax now tested w/ 2 doses in 40 people 55 & up; mean age 69. No serious adverse events noted thru 57 days. A few symptoms: headache, injection-site pain. Vax officially known as mRNA-1273 https://t.co/blXGHZzo37
Will you be joining us this December? We hope so! And as such we want you to know that you can save $560 on your pass this week ONLY. Offer ends at midnight tomorrow - don't miss out! https://t.co/gDTqlfqOka
Shoutout to the recent additions to the 2020 delegate list! With over 100 #RNA experts now in the room, this is shaping up to be quite a meeting. Get involved: https://t.co/sWOVIbSr9O
Panel Discussion: From Theory to Reality: How to Target RNA Biology with Small Molecule Approaches. Join @ArrakisTx, @AnimaBiotech & @LillyPad to discuss successful methods, utilize industry achievements & overcome key challenges. Find out more: https://t.co/Xtm1cJkb5F
Learn how @scrippsresearch, @Roche, @ArrakisTx and more are advancing their #RNA targeted small molecule therapeutics & gain insight into translating RNA targeted small molecule discoveries into clinical development. Full speaker line-up and agenda here: https://t.co/Gd1v9f5wOm
The Moderna mRNA vaccine, which elicited antibodies and T cells specific for the Covid-19 virus in adults 55 years of age or younger, elicited similarly high levels of neutralizing-antibody and CD4 T-cell responses in older adults.
#COVID19#SARSCoV2
An interesting difference between the Moderna and Pfizer mRNA vaccines. Moderna RNA is more stable at temperatures of +4 to -20 degrees Celsius whereas the Pfizer vaccine needs to be maintained at -80 which will significantly limit distribution. https://t.co/gSyYrvoLYg
This week ONLY you can save $805 on your ticket to this year's summit. But did you know that you can access extra discounts ON TOP OF this saving when you register as a group? Claim yours today: https://t.co/azINxp86gg
Our CSO, Jen Petter, offers a Dark Matter Blog post that chronicles how a small molecule drug just approved by FDA, #risdiplam, is able to bind to RNA to treat spinal muscular atrophy #SMA, stepping onto the stage with oligo and gene therapy drugs. https://t.co/XjKYZC6ir9
Prelude Therapeutics gets $50M Series C funding to support Prelude’s oncological research focused on using small-molecule inhibitors as a cancer therapy. Meet Kris Vaddi, founder and CEO
https://t.co/q0btjAkpmr